Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838860 | 0.85 | EGLN3 (1.00) | EGLN3TDP1SMN1; SMN2HTTAPAF1 | |
| SCHEMBL30389756 | 0.85 | EGLN3 (1.00) | EGLN3TDP1SMN1; SMN2HTTAPAF1 | |
| SCHEMBL6852835 | 0.84 | EGLN3 (0.74) | EGLN3TDP1SMN1; SMN2HTTAPAF1 | |
| SCHEMBL10881570 | 0.83 | KDM4E (0.65) | EGLN3TDP1SMN1; SMN2HTTAPAF1 | |
| SCHEMBL3044408 | 0.83 | EGLN3 (0.68) | EGLN3TDP1SMN1; SMN2HTTAPAF1 | |
| SCHEMBL28299392 | 0.81 | EGLN3 (0.70) | EGLN3TDP1SMN1; SMN2HTTAPAF1 | |
| SCHEMBL4064250 | 0.81 | EGLN3 (0.65) | EGLN3TDP1SMN1; SMN2HTTAPAF1 | |
| SCHEMBL13588038 | 0.81 | EGLN3 (0.65) | EGLN3TDP1SMN1; SMN2HTTAPAF1 | |
| SCHEMBL6442808 | 0.80 | TDP1 (1.00) | EGLN3TDP1SMN1; SMN2HTTLMNA | |
| SCHEMBL17309670 | 0.80 | KDM4E (0.74) | EGLN3TDP1SMN1; SMN2HTTAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0089894-B1 | N-(2-(4-HYDROXY-3-METHOXY-PHENYL)-2-HYDROXY-ETHYL)-3-AMINO-1(1-BENZIMIDAZOLYL) BUTANE AND SALTS AND HYDRATES WITH BETA-ADRENERGIC ACTIVITY, THERAPEUTICAL APPLICATIONS AND PROCESS FOR THEIR PREPARATION | Société anonyme dite: LABORATOIRE ROGER BELLON (FR) | 1986-06-11 | — | — | EP | claimed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | PFIZER LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| WO-2008050207-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LIMITED (GB) | 2008-05-02 | — | — | WO | disclosed |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | PFIZER LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| US-4434174-A | Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1984-02-28 | — | — | US | disclosed |
| US-4363808-A | N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1982-12-14 | — | — | US | disclosed |
| EP-0034116-A2 | N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1981-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | ADRB2, ADRB1, ADRA2C | EGLN3 1787/4885TDP1 2966/4885SMN1; SMN2 1803/4885 |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | ADRB2, ADRB1, ADRA2C | EGLN3 2315/4885TDP1 4088/4885SMN1; SMN2 2020/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | EGLN3 348/4885TDP1 768/4885SMN1; SMN2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.